Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Gastric cancer is the second cause of cancer related death and China has the most gastric
cancer patients in the world. Although systemic strategies, including adjuvant chemotherapy,
postoperative chemoradiotherapy, perioperative chemotherapy, have evolved and showed benefits
these years, the prognosis of advanced gastric cancer is still not satisfactory. Optimal
regimens and optimal method administration is still being found. Neoadjuvant chemotherapy has
many advantages, including downstaging the tumor, increasing R0 rate, early eradicating of
micrometastasis. In previous trials, combination of paclitaxel and s-1 has showed safety and
tolerance in recurrent or metastatic gastric cancer. Using liposome as a carrier, paclitaxel
has a better histocompatibility and cellular affinity, resulting a improved stability and
reduced toxicity. In this phase II trial, we are going to study the safety and feasibility of
paclitaxel liposome plus s-1 as neoadjuvant chemotherapy.